129 related articles for article (PubMed ID: 38479497)
41. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
[TBL] [Abstract][Full Text] [Related]
42. PREVENTION OF HEART FAILURE PATIENTS WITH DECREASED EJECTION FRACTION IN NON-CARDIAC SURGERY: LEVOSIMENDAN OR ANESTHETIC CARDIOPROTECTION?
Likhvantsev VV; Marchenko DN; Grebenshchikov OA; Ubasev YV; Zabelina TS; Timoshin SS; Skripkin YV; Ovezov AM; Lar'kov RN; Philippovskaya ZS; Sungurov VA
Anesteziol Reanimatol; 2016 Nov; 61(6):411-417. PubMed ID: 29894607
[TBL] [Abstract][Full Text] [Related]
43. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
44. Effects of levosimendan on ventriculo-arterial coupling and cardiac efficiency in paediatric patients with single-ventricle physiology after surgical palliation: retrospective study.
Iacobelli R; Ricci Z; Marinari E; Haiberger R; Di Molfetta A; Toscano A; Di Chiara L
Interact Cardiovasc Thorac Surg; 2020 Apr; 30(4):623-629. PubMed ID: 31986196
[TBL] [Abstract][Full Text] [Related]
45. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
46. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.
Antcliffe DB; Santhakumaran S; Orme RML; Ward JK; Al-Beidh F; O'Dea K; Perkins GD; Singer M; McAuley DF; Mason AJ; Cross M; Ashby D; Gordon AC
Intensive Care Med; 2019 Oct; 45(10):1392-1400. PubMed ID: 31428804
[TBL] [Abstract][Full Text] [Related]
47. Levosimendan in patients with low cardiac output syndrome undergoing cardiac surgery: A systematic review and meta-analysis.
Zhu J; Zhang Y; Chen L; He Y; Qing X
Anaesth Crit Care Pain Med; 2019 Jun; 38(3):243-249. PubMed ID: 30342103
[TBL] [Abstract][Full Text] [Related]
48. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
McLean AS; Huang SJ; Nalos M; Ting I
J Cardiovasc Pharmacol; 2005 Dec; 46(6):830-5. PubMed ID: 16306809
[TBL] [Abstract][Full Text] [Related]
49. Effect of Levosimendan on Renal Outcome in Cardiac Surgery Patients With Chronic Kidney Disease and Perioperative Cardiovascular Dysfunction: A Substudy of a Multicenter Randomized Trial.
Zangrillo A; Alvaro G; Belletti A; Pisano A; Brazzi L; Calabrò MG; Guarracino F; Bove T; Grigoryev EV; Monaco F; Boboshko VA; Likhvantsev VV; Scandroglio AM; Paternoster G; Lembo R; Frassoni S; Comis M; Pasyuga VV; Navalesi P; Lomivorotov VV;
J Cardiothorac Vasc Anesth; 2018 Oct; 32(5):2152-2159. PubMed ID: 29580796
[TBL] [Abstract][Full Text] [Related]
50. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.
van Diepen S; Mehta RH; Leimberger JD; Goodman SG; Fremes S; Jankowich R; Heringlake M; Anstrom KJ; Levy JH; Luber J; Nagpal AD; Duncan AE; Argenziano M; Toller W; Teoh K; Knight JD; Lopes RD; Cowper PA; Mark DB; Alexander JH
J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2302-2309.e6. PubMed ID: 31358329
[TBL] [Abstract][Full Text] [Related]
51. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Uhlig K; Efremov L; Tongers J; Frantz S; Mikolajczyk R; Sedding D; Schumann J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009669. PubMed ID: 33152122
[TBL] [Abstract][Full Text] [Related]
52. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine.
Yilmaz MB; Yalta K; Yontar C; Karadas F; Erdem A; Turgut OO; Yilmaz A; Tandogan I
Cardiovasc Drugs Ther; 2007 Dec; 21(6):431-5. PubMed ID: 17952581
[TBL] [Abstract][Full Text] [Related]
53. Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.
Cholley B; Caruba T; Grosjean S; Amour J; Ouattara A; Villacorta J; Miguet B; Guinet P; Lévy F; Squara P; Aït Hamou N; Carillion A; Boyer J; Boughenou MF; Rosier S; Robin E; Radutoiu M; Durand M; Guidon C; Desebbe O; Charles-Nelson A; Menasché P; Rozec B; Girard C; Fellahi JL; Pirracchio R; Chatellier G;
JAMA; 2017 Aug; 318(6):548-556. PubMed ID: 28787507
[TBL] [Abstract][Full Text] [Related]
54. Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Shang G; Yang X; Song D; Ti Y; Shang Y; Wang Z; Tang M; Zhang Y; Zhang W; Zhong M
Am J Cardiovasc Drugs; 2017 Dec; 17(6):453-463. PubMed ID: 28597399
[TBL] [Abstract][Full Text] [Related]
55. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
56. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.
Cholley B; Levy B; Fellahi JL; Longrois D; Amour J; Ouattara A; Mebazaa A
Crit Care; 2019 Nov; 23(1):385. PubMed ID: 31783891
[TBL] [Abstract][Full Text] [Related]
57. The ADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patients with advanced decompensated heart failure.
Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Canova P; Mastropasqua F; Frigerio M; Lagioia R; Oliva F
J Heart Lung Transplant; 2014 Apr; 33(4):404-11. PubMed ID: 24485712
[TBL] [Abstract][Full Text] [Related]
58. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu Y
Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
[TBL] [Abstract][Full Text] [Related]
59. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
60. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
